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AbstrAct
Objective  To identify the limitations in palliative care 
provision in the last year of life for people with liver 
cirrhosis and potential barriers to and enablers of palliative 
care.
Design  Mixed methods, including a retrospective case 
note review, qualitative focus groups and individual 
interviews.
setting  A tertiary referral liver centre in the south of 
England (UK).
Participants  Purposively selected case notes of 30 
people with cirrhosis who attended the tertiary referral 
liver centre and died during an 18-month period; a 
purposive sample of 22 liver health professionals who 
participated in either focus groups or individual interviews.
Primary and secondary outcomes  Data collected from 
case notes included hospital admissions, documented 
discussions of prognosis and palliative care provision. 
Qualitative methods explored management of people with 
cirrhosis, and barriers to and enablers of palliative care.
results  Participants had high rates of hospital 
admissions and symptom burden. Clinicians rarely 
discussed prognosis or future care preferences; they 
lacked the skills and confidence to initiate discussions. 
Palliative care provision occurred late because clinicians 
were reluctant to refer due to their perception that reduced 
liver function is reversible, poor understanding of the 
potential of a palliative approach; palliative care was 
perceived negatively by patients and families.
conclusions  People dying with cirrhosis have 
unpredictable trajectories, but share a common pathway 
of frequent admissions and worsening symptoms as death 
approaches. The use of clinical tools to identify the point of 
irreversible deterioration and joint working between liver 
services and palliative care may improve care for people 
with cirrhosis.
bAckgrOunD
Advanced chronic liver disease (cirrhosis) is a 
growing international public health problem 
and often affects people of working age.1 It is 
the third most common cause of premature 
death in the UK2; more people are affected 
by liver disease with the increases in alcohol 
consumption, viral hepatitis and obesity.3 
Most people dying from liver disease are not 
suitable for liver transplantation and, of those 
who are suitable, 20% will die before a donor 
becomes available.4 Living with cirrhosis 
may involve considerable symptom burden, 
and when liver failure ensues the prognosis 
is poor. Death may occur either after a long 
period of decline with a fluctuant clinical 
picture, or may be sudden and unanticipated. 
In most cases, death from cirrhosis occurs in 
hospital.5
People with cirrhosis have supportive and 
palliative care needs.6–9 Liver professionals 
acknowledge they have a role to play in this 
aspect of care,10 11 but feel that their skills are 
limited and may be inadequate to offer an 
effective palliative approach.10 12 Referrals to 
specialist palliative care (SPC) may be neces-
sary but palliative care provision is limited,13 
and knowledge of prescribing in liver failure 
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Research
strengths and limitations of this study
 ► The study is the first to look specifically at how care 
is provided to people with advanced liver disease 
in the last year of life, with the aim of identifying 
barriers that limit a palliative approach to care.
 ► A mixed methods design enables exploration from 
different perspectives of the structural difficulties to 
providing end of life care to people with advanced 
liver disease.
 ► Findings suggest pragmatic ways that supportive 
and end of life care can be improved for people with 
advanced liver disease.
 ► As this study was conducted in one tertiary liver 
unit in the south of England, the findings may not be 
generalised to other healthcare settings.
 ► The retrospective nature of the case note data limits 
the interpretation of the quantitative findings.
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is needed. Shared care, defined as using the skills and 
knowledge of many health professionals who share joint 
responsibility for an individual’s care, may be useful.14 
Palliative care offered in parallel with optimised specialist 
and generalist care may benefit people with advanced 
cirrhosis.15 One difficulty is knowing the appropriate 
time to make referrals and begin shared care.10 Further 
data to understand how different specialities such as 
liver and palliative care services can work together may 
be helpful.14 In this paper, we report what we have learnt 
from exploring practice in a tertiary treatment centre for 
liver disease in north London, UK. We used mixed meth-
odology, guided by Rapid Participatory Appraisal in which 
data collected from different sources relating to a specific 
healthcare provider are combined to describe both the 
service structure and potential care improvements in a 
specific health locality.16 Using mixed methods, we hoped 
to gain greater understanding of the limitations in the 
provision of palliative care for people with cirrhosis in 
the last year of life, and explore the reasons behind these 
limitations. This approach is commonly used in health 
service research to understand the complexity of health-
care.17
We conducted a case note review, focus groups and 
qualitative interviews to explore:
1. how healthcare in liver services is provided in the 
last year of life to people with advanced liver disease 
(cirrhosis) from any cause to identify limitations in 
palliative care provision;
2. challenges in providing palliative care provision in 
liver care and how this provision might be improved 
in hepatology.
MeThod
A mixed methods study, using a retrospective case note 
review, qualitative focus groups and individual interviews. 
Case note findings were used to quantify the types of 
healthcare inputs provided by the liver services to people 
in their last year of life and to identify potential limita-
tions in and barriers to the palliative care provided and a 
shared approach to care. The qualitative data identified 
reasons underlying these limitations and barriers, and 
highlighted potential enablers to improving care in this 
context.
setting
A tertiary referral liver transplant centre in north London 
UK, providing both a core diagnostic service for all condi-
tions affecting the liver and long-term management of 
patients with all severities of liver disease.
Procedure
Retrospective case note review
As resources were limited, we purposively selected 30 
people with cirrhosis from the 66 people who attended 
the tertiary referral liver centre and died between April 
2010 and September 2011. We aimed to ensure that our 
sample represented the spectrum of people attending 
the centre and purposefully sampled according to age, 
gender and cause of liver failure.
We used a structured framework to extract data 
from patient records available from the centre for 
the 12-month period prior to death. We noted demo-
graphics, severity of liver disease at last admission, cause 
of cirrhosis, transplantation status, physical and psycho-
logical symptoms, and health service use in secondary 
care (inpatient admissions, hospital length of stay, inten-
sive therapy unit (ITU) and liver-related procedures). 
We recorded documented evidence of discussions about 
prognosis and future preferences for care. We collected 
information on referrals to SPC, creation of care plans 
including evidence of advance care planning (ACP), 
resuscitation (do not attempt cardiopulmonary resusci-
tation (DNACPR)) status, preferred place of death and 
actual place of death. Data were extracted by the research 
nurse (SD) and inputted into Microsoft Excel.
Qualitative data
Both focus groups and semistructured interviews were 
used to capture as many views of healthcare professionals 
as possible. All potential participants were first identi-
fied by a clinician (LG). The research nurse (SD) then 
contacted these participants face to face, by telephone or 
by email. Participants were given information about the 
study, outlining the role of the research team, and gave 
written consent prior to data collection. All participants 
took part either in one focus group or a semistructured 
interview (between July 2013 and May 2014), which were 
conducted in the liver centre.
Focus groups
Focus groups were used as a pragmatic method of gath-
ering larger numbers of people and using the group 
dynamic to generate discussion about care at the end 
of life in cirrhosis.18 19 Purposive sampling was used to 
ensure the views of those at all levels of the liver team 
across the disciplines (doctors, nurses and allied health 
professionals) were captured. Three focus groups were 
organised (each lasting 45–60 min) and led by a research 
nurse (SD—Master’s degree qualification and 6 years 
of qualitative research experience), with an observer 
(JL—senior health researcher with a PhD and 20 years 
of experience in qualitative/mixed methods research) 
taking field notes and cofacilitating.
topic guide
To guide discussions, a topic guide (online supple-
mentary appendix 1) was developed by the members 
of research team (JL, SD, AM, DT, LG, KH and LJ) 
covering: challenges of providing care to people in the 
last year of life; their perception of patient and family 
understanding of liver disease; discussing prognosis 
and future care preferences; improving palliative care. 
This guide was developed pragmatically in the context 
of liver disease, guided by the principles of palliative 
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Table 1 Patient demographics and clinical characteristics
Characteristic n (%) (N=30)
Demographics
Age
  Mean (SD) 58 (11)
  Min–max 25–79
Gender
  Male 20 (67)
  Female 10 (33)
Ethnicity (n=24)
  White British 14 (58)
  Black African 2 (8)
  Asian 4 (17)
  Other 4 (17)
Relationship status (n=26)
  Married 14 (54)
  Divorced 5 (19)
  Partner (previously divorced) 6 (23)
  Widowed 1 (4)
Living arrangements (n=28)
  With wife/partner 8 (35)
  With wife and children 2 (9)
  With children 3 (13)
  With friends 2 (9)
  Alone 5 (22)
  Hostel 2 (9)
  Hotel 1 (4)
Clinical characteristics
Cause of cirrhosis
  Alcoholic liver disease (ALD) 11 (37)
  Hepatitis C (Hep C), ALD 3 (10)
  Hepatocellular carcinoma (HCC), Hep C, 
ALD 1 (3)
  HCC, Hepatitis B (Hep B), Hep C, ALD 1 (3)
  Hep C 4 (13)
  Hep C, HCC 3 (10)
  Non-alcoholic steatohepatitis (NASH) 2 (7)
  NASH, HCC 1 (3)
  Other (primary biliary cirrhosis, 
antitrypsin) 2 (7)
Previous transplant 2 (7)
On transplant list 5 (17)
care.20 All focus groups were audiotaped and tran-
scribed verbatim.
Interviews
Professionals unable to attend the focus groups, 
were invited to take part in semistructured individual 
interviews. Nine interviews were conducted by SD (lasting 
18–70 min) using the topic guide, and were audiotaped 
and transcribed verbatim.
DAtA AnAlysIs
Retrospective case notes
Descriptive statistics were used to describe hospital admis-
sions and service use, documentation of prognostic 
discussions and preferences for future care, and palliative 
care provision. Data were summarised to highlight limita-
tions in palliative care service provision.
Qualitative data
A framework approach was used to analyse the tran-
scripts,21 which were first read independently by two 
researchers (JL and SD). Themes were identified, from 
which a coding system was developed and applied to 
the whole data set systematically. Any disagreements 
in coding were resolved by consensus. In organising 
the data into appropriate themes, Microsoft Excel 
was used. The researchers considered themes inde-
pendently and met to discuss the themes identified and 
how they were linked together by contextual factors. 
Independent analysis ensured validity and reliability 
of the themes and links identified. Findings were also 
shared with our clinical partners (AM, LG, DT and 
KH) in the research team to ensure that the findings 
were consistent with their experience of current clin-
ical practice. These themes were used to explain the 
limitations in palliative care provision found in the 
case notes, and to identify barriers and enablers to 
future palliative care for people with cirrhosis.
Ethical approval
Ethical approval was sought, but deemed unnecessary by 
the NRES Committee London—West London & GTAC 
(ref 14/LO/0799). NHS permission to conduct the clin-
ical case note review and the qualitative interviews with 
liver health professionals was obtained from the Royal 
Free London Clinical Governance Lead for Hepatology 
and Palliative Care under the remit of health service 
improvement.
rEsults
Provision of healthcare in last year of life (case note 
findings)
Demographics and clinical characteristics (table 1)
Patient demographics and clinical characteristics 
are provided in table 1. Our sample was predom-
inately male (n=20, 67%) with a median age of 59 
years (IQR: 52–66; range 25–75), in which alcohol-re-
lated liver disease was the predominant diagnosis 
(n=16; 53%). A Model for End-stage Liver Disease 
(MELD) score gives an indication of short-term 
mortality, and is used to prioritise candidates on 
the orthotopic liver transplantation waiting list. In 
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Table 2 Signs and symptoms during the last 3 months for 
the 30 patients
Medical condition n (%)
Pain 24 (80)
  Abdomen 15 (50)
  Back 6 (20)
  Legs 4 (13)
  Chest 4 (13)
  Ribs 2 (7)
Ascites 19 (63)
  Distended abdomen 12 (40)
  Tense abdomen 6 (20)
Encephalopathy 19 (63)
  Confusion 11 (37)
  Asterixis, hepatic flap 10 (33)
  Drowsiness 8 (27)
  Tremor 5 (17)
  Refusing treatment 4 (13)
  Agitation 4 (13)
  Distressed 2 (7)
  Crying, upset 2 (7)
  Aggressive 2 (7)
  Shouting/screaming 2 (7)
  Disorientated 2 (7)
Bleeding 12 (40)
  Blood in faeces 4 (13)
  Blood in vomit 3 (10)
  Coffee ground vomit 3 (10)
  Bleeding from rectum 4 (13)
  Bruising under skin 3 (10)
  Bleeding from mouth/nose 2 (7)
  Bleeding from penis 2 (7)
  Blood in urine 2 (7)
Peripheral oedema 7 (23)
  Sacrum, testicles, scrotum 6 (2)
  Legs, thighs 3 (10)
  Ankles, feet 3 (10)
 Skin other
  Pruritus 7 (23)
  Rashes, erythema 5 (17)
  Cellulitis 3 (10)
Fatigue 2 (40)
Weakness (tiredness, lethargy) 9 (30)
Sepsis 8 (27)
  Tachycardia 4 (13)
  Temperature, chills/rigours 4 (13)
Psychological 10 (33)
Continued
Medical condition n (%)
  Distressed, crying, upset 4 (13)
  Depressed 4 (13)
  Low mood 3 (10)
  Hallucinations 3 (10)
  Anxious 2 (7)
  Refusing treatments/
observations
2 (7)
  Insomnia 2 (7)
  Suicidal 2 (7)
Digestive system
  Anorexia 11 (37)
  Nausea 11 (37)
  Vomiting 10 (33)
  Incontinent of faeces 10 (33)
  Constipation 6 (20)
  Diarrhoea 4 (13)
Respiratory
  Shortness of breath 17 (57)
  Secretions 4 (13)
  Wheezy 2 (7)
Urinary system
  Incontinent of urine 8 (27)
  Oliguria 8 (27)
Other
  Confusion (variety of causes) 6 (20)
  Unsteady on feet/gait 9 (30)
  Dizzy and faint 4 (13)
  Agitation 112 (7)
Table 2 Continued 
23 cases where data were available at last admission, 
our sample had a median (IQR) MELD score of 23 
(16.5–23), suggesting a 19.6% chance of dying in the 
next 3 months.22 Nineteen (63%) people were not 
considered for liver transplant due to poor health, 
four were on the transplant waiting list and three had 
previously received a transplant. Eight (27%) people 
with cirrhosis had been referred to the tertiary centre 
from ‘out of area’ hospitals either for a liver trans-
plant assessment, or for specialist treatments, such 
as a transjugular intrahepatic portosystemic shunt 
(TIPS) or intensive management of bleeding.
The people in our sample were highly symptom-
atic (table 2). All were symptomatic 3 months before 
death, presenting with ascites (n=22, 73%), extensive 
peripheral oedema (n=20, 66%), severe fatigue and 
weakness (n=20; 66%), and pain (n=13; 43%). In the 
last month of life, our participants presented with 
an average of 14 physical symptoms per person. The 
majority (n=19, 63%) were noted to have symptoms of 
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hepatic encephalopathy, such as confusion, disorienta-
tion and agitation.
Health service use in tertiary care
Our sample of 30 had a median of three inpatient admis-
sions (IQR: 2–5) per person in the last year of life, and 
a median length of stay of 31 days (IQR: 19–55). Seven-
teen (57%) people were readmitted within 30 days of 
discharge. The frequency of admissions increased for 
most people (n=29; 97%) in the last 3 months of life. 
Nineteen (63%) people had more than one admission 
in the month before death, during which the median 
number of admissions was two (IQR: 1–3). Of the 78 
admissions precipitated by cirrhotic complications, 
most required invasive procedures, such as paracen-
tesis (n=53/78, 68%), blood transfusions (n=13/78, 
17%), endoscopic variceal banding (n=4/78, 5%) and 
TIPS (n=4/78, 5%). During these admissions, each 
participant was seen in the last year of life by a mean 
of three different liver consultants (range 1–6). Nine 
(30%) people were regularly reviewed by the hospital 
nurse-led patient-at-risk team (PART), to decide 
whether to escalate or de-escalate their treatment. Six 
(20%) people with cirrhosis required treatment in 
the intensive therapy unit (ITU) during which three 
patients died.
Documentation of prognosis, future care discussions and palliative 
care provision
Liver consultants recorded having discussed prognosis 
mainly with family members (n=23, 77%); discussions 
occurred very late, in 16 (53%) cases≤34 days before 
the person died. Liver doctors recorded fewer discus-
sions with patients about understanding of their disease 
or future care preferences (n=16, 53%), most of which 
occurred 1 month before death (n=9/16; 56%).
Although most people (n=26; 67%) had a DNACPR 
decision recorded in their medical notes, this was 
completed by medical personnel, with limited consul-
tation with either the person with cirrhosis (n=5, 17%) 
or their family member (n=6, 20%). In seven cases, 
the liver team had to be alerted about completing a 
DNACPR by other clinicians such as the PART team 
(n=4), ITU (n=2) or the emergency department (n=1). 
Most people (n=19, 63%) had no discussions with 
doctors about their preferred place of care.
Most people with cirrhosis (n=21; 70%) were 
referred to SPC a median of 5 days before death. 
Twelve (40%) people with cirrhosis documented as 
deteriorating were still receiving active treatment up 
until their death. For most people, death occurred 
in hospital (n=25; 83%), three died in ITU. The 
remaining five people died either at home (n=3; 
10%) or in a hospice (n=2; 7%). Only five people 
from the sample had clear discussions with health 
professionals about place of death; two of these died 
in the place of their choice (one at home and the 
other in hospital).
Challenges to and enablers of provision of palliative care 
(qualitative data)
Demographics of liver clinician sample
Thirteen liver health professionals took part in three 
focus groups (FG;  FG1: three doctors, two liver transplant 
nurses, a dietician and a pharmacist; FG2: three ward 
nurses and a healthcare assistant; FG3: two ward nurses). 
Nine health professionals took part in semistructured 
interviews (five doctors, two senior nurses in hepatology, 
a clinical nurse specialist in palliative care and an alcohol 
liaison nurse). No demographic information was collected 
for the liver clinician sample other than their discipline.
key findings
Initial analysis illustrated that liver clinicians recognised 
that although their patients were in poor health, they 
did not address quality of life issues with them and pallia-
tive care options were only considered with patients who 
raised this topic themselves. Further analysis identified 
five emergent themes which illustrated why liver clinicians 
focused on reactive treatment for people at the expense 
of palliative care: unpredictable trajectory of liver disease, 
management of patient treatment expectations, clini-
cian/patient perceptions of the palliative care role, poor 
continuity of care, perceived lack of skill and confidence.
unpredictable trajectory of liver disease
 The perceived ability of the liver to recover function made 
it difficult for doctors to estimate the point of irrevers-
ible liver decline, and so provided doctors with hope that 
trying different treatments would promote recovery, even 
with patients on the wards who were imminently dying. 
Nurses felt that part of this difficulty was the short periods 
that doctors spend with patients in contrast with the ward 
nurses, who provide continuous care and were confident 
in identifying those imminently dying. However, nurses 
considered that cessation of active treatment was the 
responsibility of doctors as main clinical decision makers.
We (ward nurses) have constant contact with 
patients… enables us to identify those patients who 
are both aware of their deterioration and want to 
die at home to be fast tracked to specialist palliative 
care. Ward nurse, Nurse focus group 1.
Management of patient expectations
 Doctors’ emphasis on active treatments is reinforced 
by their own perceptions of patients’ treatment expec-
tations. Part of this expectation may be reflected by the 
patients’ younger ages, who doctors feel want life at all 
costs. Furthermore, as many patients are referred by 
secondary care ‘out of area’ (as illustrated in our case 
notes), clinicians perceive these patients see referral to 
the tertiary liver centre as a last chance to ‘cure’ their liver 
disease. This in turn, reinforces clinicians’ focus on active 
treatments, at the expense of discussing prognostic issues.
We probably don’t do enough of it (discuss future 
care preference), because most of the patients 
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at a given time are not willing to engage with that 
question. The median age of patients is 53, so we are 
not talking about an 80 year old who has lived their 
life to the full. We are talking about people who still 
want life. (Consultant hepatologist 1, interview)
Patients’ unrealistic expectations, and their limited 
knowledge and understanding of their own disease, 
presented doctors with difficulties in managing these 
expectations and deciding what treatment options to 
pursue.
They (patients) are often referred extremely late, full 
of expectation only to be told there’s nothing we can 
do. The difficulty is, what do you then do with that 
patient? Do you let them go back to the referring 
trust or secondary care, how do you know that they 
are going to get palliative care or the treatment that 
they need. (Consultant hepatologist 2, interview)
Misunderstanding of palliative care
Clinicians perceived that patients and their family 
members saw referral to palliative care negatively, as a 
move suggesting that clinicians had ‘given up’ on the 
patient. They felt that patients and families did not under-
stand what palliative care could offer in terms of symptom 
control and psychosocial support, instead seeing pallia-
tive care as a service for people at the very end of life, as 
illustrated by this senior nurse.
We’ve got a patient on the ward whose family are 
very opposed to palliative care, but wanted active 
treatment. The patient has had repeated admissions, 
even if the family can only have her for another extra 
few months. The nurse tried to tell them it is not just 
the last weeks and hours (input from palliative care), 
it can be longer than that and the palliative team 
have a lot to offer you even now. (ward senior nurse, 
interview)
Although most liver clinicians saw a role for palliative 
care, the debate on its utilisation centred more on under-
standing when a referral to palliative care was considered 
appropriate. Most had very limited experience in working 
with palliative care and were unsure of the best time to 
refer. This was further compounded by the difficulty of 
estimating the point of irreversible liver deterioration 
and the lack of clinical tools and guidelines to support 
them with this process.
Would like to refer much earlier, but need to 
have an understanding at the point that specialist 
palliative care would like involvement. (Consultant 
hepatologist, Multi-disciplinary focus group)
Poor continuity of care
Liver clinicians felt the lack of adequate information 
systems and the rotation of medical staff (our case notes 
showed that each participant saw at least three liver consul-
tants over the year), contributed to ‘poor continuity of 
care’. This lack of continuity is demonstrated when treat-
ment plans agreed with one consultant can be changed by 
another consultant due to a lack of shared information.
This rotation of staff causes problems as some 
patients are treated and patched up, but come in 
under another consultant when readmitted and 
treatment happens again. However, the system 
does not allow for information to be exchanged 
about what exact changes have occurred in their 
condition. (Consultant hepatologist 3, interview)
Perceived lack of skill and confidence
Both doctors and nurses perceived they lacked skills and 
confidence in engaging in discussions about prognosis or 
palliative care with patients or family members. On liver 
wards, this was further compounded by a lack of private 
space to discuss sensitive topics.
Enablers for improved palliative care
Liver clinicians suggested strategies to enhance both 
continuity and integration of palliative care and liver 
services, such as joint liver and palliative care clinics for 
people with decompensated liver disease and multidis-
ciplinary team case conferences to coordinate care and 
treatment for those patients frequently admitted. Such 
initiatives would enhance mutual understanding across 
specialities of liver-specific symptom management and 
the timing of referrals. To support liver clinicians in iden-
tifying patients suitable for early palliative care support, 
appropriate clinical tools with relevant guidelines need 
to be identified.
DIscussIOn
Key summary
Our findings reflect the complicated clinical picture 
surrounding the provision of care of people with cirrhosis 
in their last year of life. We demonstrate that patients 
have a high symptom burden, increasing number of 
admissions in their last 3 months of life and a focus on 
active, disease-directed treatments. As with previous 
studies,12 13 we highlight poor palliative care provision, 
in which discussions about prognosis and resuscitation 
orders were only raised in the last few days of life and 
referrals to palliative care were made very close to death. 
We found that liver clinicians have difficulties in initi-
ating discussions regarding prognosis, do not engage in 
parallel planning for potential deterioration as well as 
recovery and have a limited knowledge of palliative care.
Studies suggest that uncertainty is an important barrier 
to anticipatory care planning in advanced liver disease.12 
Our qualitative data further illustrate how five key factors 
interact as barriers to palliative care. Although liver 
clinicians may wish to refer patients to palliative care 
earlier, active treatment is usually the de-facto choice 
unless patients themselves specifically raise the topic. 
The difficulty of identifying the point of irreversible liver 
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deterioration, patients’ expectations of finding a cure, 
together with liver clinicians’ perceived lack of confidence 
and skills in addressing palliative care issues enabled a 
focus on active treatment. A further barrier is the lack 
of contact and experience that liver clinicians have of 
working with palliative care specialists. This prevents 
them from understanding what palliative care can offer, 
and prevents palliative care clinicians from establishing 
earlier contact with patients which might enable them 
to become familiar faces for patients and families. This 
culture of active treatment may stem from tertiary centres 
being seen as at the forefront of technical innovation.
clinical implications
Our findings suggest that lack of knowledge about 
the role and potential benefits of palliative care may 
contribute to the late referral of liver patients to SPC. 
The formation of liver clinics specifically for people with 
decompensated liver failure, with joint input from liver 
and palliative care specialists is recommended. This may 
promote understanding across specialties, an integrated 
and timely approach to care, formulation of treatment 
plans and a reduction in unplanned inpatient admissions 
to the liver service.12 It may also improve symptom control 
and enable clinicians to engage in discussions about 
prognosis and future care preferences with patients and 
families at an earlier stage. Previous studies have shown 
that early referral to SPC may reduce the rates of expen-
sive hospitalisation, especially in the last month of life.23 
Such service developments could be explored, in line 
with guidance set by the ‘End of life care good practice 
guide’.24 Consideration should be given to the care philos-
ophy in a tertiary liver transplant centre, where many liver 
clinicians are reluctant to accept that active interventions 
have limited patient benefit. Qualitative data indicate 
that liver clinicians found it difficult to identify the point 
of irreversible liver deterioration; our case note findings 
suggest that inpatient admissions and symptoms increase 
in frequency in the last 3 months of life. The introduction 
of clinical tools such as the Supportive and Palliative Indi-
cators Care Tool25 may support clinicians to identify when 
is timely to refer to palliative care, such as the ‘point of 
irreversible deterioration of liver function’.
strengths and limitations
Our study explores care in advanced liver disease from 
different perspectives, but we accept our methodology 
limits the generalisability of our interpretation. Our case 
note data were retrospective and limited by the quality of 
recording in medical notes. Many in our case note sample 
were referred from other hospitals and did not include 
data recorded at these sites. Due to time constraints, we 
reviewed a purposive sample of case notes of those who 
died, so there is a potential for selection bias and error 
in the notes that were reviewed. Our case note sample 
only reflects patients who died during follow-up and not 
those who were still alive, or who had a transplant. This is 
important since these patients are also often recipients of 
palliative care. For our qualitative arm, the health profes-
sionals were recruited from one hospital site and due to 
both time constraints and the limited pool of participants 
available, it is possible that theme saturation was not fully 
achieved. We did not explore the views of close family 
members and informal carers in this study and may have 
missed important insights on experiences of living and 
dying with liver disease and how care might be improved. 
Our findings reflected practice in a tertiary liver trans-
plant specialist unit in one country; while clinical issues 
are likely to be similar in other settings, organisational 
issues and person-centred attitudes will vary across other 
healthcare systems. Nevertheless, our exploratory find-
ings do provide new insights into how care towards the 
end of life could be improved in people with cirrhosis, 
which deserve further exploration using more robust 
methodology.
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